Abstract:
The subject invention concerns a method for therapeutically treating a patient afflicted with autoimmune disorders or disease. The subject method comprises administering to a patient a purified antibody composition that is capable of binding to and inhibiting self-reactive pathogenic antibodies present within the patient. Specifically exemplified is a method for treating systemic lupus erythematosis wherein the antibody composition administered to the patient comprises purified anti-DNA anti-idiotypic antibodies. The subject invention further concerns a method for purifying from pooled human gamma globulin preparations anti-idiotype antibodies useful in the present therapeutic method. The present invention further concerns the purified antibody composition used in the present therapeutic method.
Abstract:
The subject invention concerns the novel use of formyl-CoA transferase enzyme together with oxalyl-CoA decarboxylase enzyme for the detection and measurement of oxalate in biological samples. The use of the enzyme system according to the subject invention results in the conversion of oxalate into carbon dioxide and formate. Because the production of formate is directly correlated to the concentration of oxalate present in a sample, the determination of the resulting formate concentration provides an accurate, sensitive and rapid means for detecting even low levels of oxalate. The subject invention further concerns the cloning, sequencing and expression of the genes that encode the formyl-CoA transferase enzyme and the oxalyl-CoA decarboxylase enzyme of Oxalobacter formigenes. The subject invention also concerns methods for detecting the presence of Oxalobacter formigenes organisms in a sample, and the polynucleotide probes and primers used in the detection method.
Abstract:
The present invention is a continuous process of producing an object with radially-varying material properties. These objects can be cylindrical forms made from polymeric materials. This process requires a novel device. The device can be used to produce high bandwidth gradient-index plastic optical fiber (GRIN-POF). This fiber is highly advantageous for use in high speed local area networks (LANs) as well as other short-range optical communication applications. The device can also be used to produce GRIN lenses which can be used in the focusing and transmission of images.
Abstract:
The subject invention pertains to novel variants of the maize gene, Shrunken2 (Sh2) and a method of using that gene. The variant gene, Sh2-m1Rev6, encodes a subunit of the ADP-glucose pyrophosphorylase (AGP) enzyme that has additional amino acids inserted in or near the allosteric binding site of the protein. Corn seed expressing the Sh2-m1Rev6 gene has a 15 % weight increase over wild type seed. The increase in seed weight is not associated simply with an increase in percentage starch content of the seed.
Abstract:
The subject invention pertains to modified plant virus genes which confer resistance on plants against geminivirus infection. A modified AV1 gene of tomato mottle geminivirus, was subcloned into an appropriate expression vector and transformed into tobacco plants. Expression of the modified gene conferred resistance against viral infection to the plant in which it was expressed. The present invention further concerns a method for conferring viral resistance on a plant. The invention also concerns modified coat protein genes, and fragments thereof, which confer viral resistance on a plant.
Abstract:
Oligonucleotides, and compositions thereof, are disclosed which can be administered to human subjects to inhibit the expression of angiotensinogen to thereby control angiotensinogen induced hypertension.
Abstract:
The present invention includes interferon-tau (IFN tau ) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
Abstract:
Disclosed are compositions comprising murine Lyst1 and Lyst2 genes and human LYST1 and LYST2 genes. Also disclosed are the Lyst1, Lyst2, LYST1, and LYST2 proteins encoded by these genes, respectively. Also disclosed are methods of using these genes in identifying patients with Chediak-Higashi Syndrome and detecting CHS-related nucleic acid and/or protein sequences. Also disclosed are methods for the recombinant expression of LYST1, Lyst1, LYST2, and Lyst2 polypeptides, antibodies raised against these polypeptides, and therapeutic approaches to treatment of autoimmune diseases and certain types of tumors. Assays for detection of the gene mutations resulting in CH Syndrome, as well as diagnostic probes for the detection of Lyst1, Lyst2, LYST1, and LYST2 genes are also provided.
Abstract:
Disclosed are novel pancratistatins and methods for their total asymmetric synthesis. In particular embodiments, processes for the total asymmetric synthesis of (+)-pancratistatin, (-)-pancratistatin, (+)-7-deoxypancratistatin, (-)-7-deoxypancratistatin, truncated pancratistatins, and related derivatives are provided.